Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue. Our complementary analyses of transcriptomic datasets f...

Full description

Bibliographic Details
Main Authors: Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
IL-23
IL-23p19 subunit inhibitors
guselkumab
risankizumab
CD64
in vitro cellular assays
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1532852/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1532852/full

Similar Items